Navigation Links
EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
Date:10/23/2008

s are key regulators of the process of mitosis, or cell division, and are often over-expressed in human cancers. In addition to the Aurora A isoform, ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets. ENMD-2076 is currently in a phase 1 clinical study in advanced cancer patients.

Dr. Mark R. Bray, Vice President Research at EntreMed commented on the presentation, "The exciting work presented by Dr. Tentler and his colleagues underscores the exceptional promise of ENMD-2076 as a novel anticancer therapeutic. Advanced non-invasive imaging using PET and DCE-MRI greatly increased the ability to monitor the antiangiogenic and antiproliferative mechanisms of ENMD-2076. We anticipate employing these techniques in upcoming ENMD-2076 clinical trials. EntreMed is actively pursing development partners for this novel oral anticancer drug candidate."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking state
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
2. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
3. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
4. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
5. Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud
6. First semiconductor-based PET scanner demonstrates potential to aid in early diagnosis of disease
7. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
8. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
9. Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial
10. ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
11. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... Beach County, Florida (PRWEB) August 27, 2014 ... Company Inc. (SCI) is announcing the creation of ... priority is to take the SCI’s philosophy of ... the company’s research and development actions are based ... , This new Scientific Advisory Board provides a ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Remcom announces ... with new features for the biomedical industry. ... enhanced Biological Thermal Sensor, exclusive to the Bio-Pro version ... version of XFdtd, developed to calculate the biological effects ... has been added to all versions to expand engineers’ ...
(Date:8/26/2014)... 2014  NeuroSigma, Inc., a Los Angeles ... technologies, today announced that it has filed a registration ... Exchange Commission relating to a proposed initial public offering ... be offered and the price range for the proposed ... LLC will act as the book-running manager for the ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... nanotubessorted by centrifuge for lengthmaterials scientists at the ... made some of the most precise measurements yet ... nanotubes become transparent, conducting sheets. Their recent experiments* ... overly short, but uniform in length nanotubes for ...
... DIEGO, Oct. 15 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ... third quarter of 2008 on Tuesday, October 21, 2008 ... President and Chief Executive,Officer, will lead the call. On ... the third quarter of 2008., The call will ...
... Reduction in Composite Events When Using Routine ... FFR Guidance in Multi-Vessel Disease, ... announced the launch of the PrimeWire(TM) Pressure,Guidewire, and the s5-FFR ... consoles in the U.S. The PrimeWire is Volcano,s newest pressure,guidewire, ...
Cached Biology Technology:Paperwork: Buckypapers clarify electrical, optical behavior of nanotubes 2Amylin Pharmaceuticals to Webcast Third Quarter Results 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 3Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 4Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 5
(Date:8/26/2014)... a protective tent over a colony of harmful ... especially difficult. Microorganisms protected in a biofilm pose ... resistance and recalcitrance to treatment, and biofilm-protected bacteria ... infections in humans and are 50 to 1,000 ... infections. , "In essence, we may have stumbled ...
(Date:8/26/2014)... increasing pressure from policymakers, consumers, and suppliers has ... beyond reducing the pollutants they emit from their ... companies must also assess environmental performance at every ... primary materials to the use and recycling of ... to the discipline known as life cycle engineering, ...
(Date:8/26/2014)... New Jersey Institute of Technology (NJIT), is helping to ... the pace for daily life. , Evolution has harmonized ... fundamental rhythms of life that include the cycle of ... change. The brain,s circadian clock controls hormone production related ... by experiences such as jet lag or night-shift work, ...
Breaking Biology News(10 mins):Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Yale journal explores advances in sustainable manufacturing 2Researching fundamental rhythms of life 2Researching fundamental rhythms of life 3
... in response to vibrations within the inner ear, could form ... way to do this could be with gene therapy that ... Emory University School of Medicine have shown that introducing a ... induce the formation of extra sensory hair cells. Their ...
... in infant rats demonstrates that the anti-epilepsy drug phenobarbital ... using the first-line drug to treat epilepsy in human ... posted online May 11, researchers at Georgetown University Medical ... to rat pups about a week old changed the ...
... findings show that embryonic stem cells unable to fully ... task: differentiation into specific cell types that give rise ... the body. Researchers from the Georgia Institute of ... required for proper embryonic stem cell differentiation to occur. ...
Cached Biology News:Gene therapy for hearing loss: Potential and limitations 2Study raises questions about use of anti-epilepsy drugs in newborns 2Study raises questions about use of anti-epilepsy drugs in newborns 3Successful stem cell differentiation requires DNA compaction, study finds 2Successful stem cell differentiation requires DNA compaction, study finds 3Successful stem cell differentiation requires DNA compaction, study finds 4
Human VASA Biotinylated Affinity Purified PAb...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
Biology Products: